REFERENCES
- Hammer R. Muscarinic receptors in the stomach. Scand J Gastroenterol 1980, 15, 5–11
- Hammer R, Berrie CP, Birdsall NJM, Burgen ASV, Hulme EC. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 1980, 283, 90–92
- Birdsall NJM, Burgen ASV, Hammer R, Hulme EC, Stockton J. Pirenzepine: a ligand with original binding properties to muscarinergic receptors. Scand J Gastroenterol 1980, 15(suppl 66), 1–20
- Hirschowitz BI, Fong J, Molina E. Effects of pirenzepine and atropine on vagal and cholinergic gastric acid secretion and gastrin release and on heart rate in the dog. J Pharmacol Exp Ther 1983, 225, 263–268
- Eltze M, Gonne M, Riedel R, Schlotke B, Schudt C, Simon WA. Pharmacological evidence for selective inhibition of gastric acid secretion by telenzepine, a new antimuscarinic drug. Eur J Pharmacol 1985, 112, 211–224
- Londong W, Londong V, Meierl A, Voderholzer, U. Telenzepine is at least 25 times more potent than pirenzepine—a dose response and comparative secretory study in man. Gut 1987, 28, 888–895
- Singer MV, Vesper J. Wirkung von Atropin auf das Pankreas. Schweiz Med Wochenschr 1979, 109, 1454–1460
- Thomas JE. An improved cannula for gastric and intestinal fistulas. Proc Soc Exp Biol Med 1941, 46, 260–261
- Singer MV, Becker S, Solomon TE, Grossman MI. Effect of adding albumin to solutions of secretin on pancreatic volume and bicarbonate response. Scand J Gastroenterol 1981, 16, 625–628
- Elashoff JD. Repeated-measures bioassay with correlated errors and heterogeneous variances: a Monte Carlo study. Biometrics 1981, 37, 475–482
- Winer BJ. Statistical principles in experimental design. 2nd ed. McGraw-Hill, New York, 1981, 120–140
- Fink M, Irwin P. EEG and behavioral effects of pirenzepine in normal volunteers. Scand J Gastroenterol 1980, 15, 39–46
- Vazquez-Echarri J, Baumgärtner D, Singer MV. Dose-response effects of atropine on pancreatic secretory response to intravenous caerulein in dogs. Pancreas 1986, 1, 341–346